Optimization of Mycophenolic Acid Therapy Using Clinical Pharmacometrics

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 1, 2014, Pages 4-11

  Dong, Min ^a   Fukuda, Tsuyoshi ^a,b   Vinks, Alexander A ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

D optimality; Inosine monophosphate dehydrogenase (IMPDH); Mycophenolic acid; Nonparametric; Pharmacodynamics; Pharmacokinetics; Pharmacometrics; Physiologically based pharmacokinetic modeling; Therapeutic drug monitoring

Indexed keywords

INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; AUTOIMMUNE DISEASE; BAYES THEOREM; CHEMICAL MODEL; CLINICAL PHARMACOLOGY; DIARRHEA; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HYDROLYSIS; DRUG MONITORING; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHROTIC SYNDROME; PHARMACODYNAMICS; PHARMACOMETRICS; REVIEW; SIMULATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; PHARMACOKINETICS; STATISTICS, NONPARAMETRIC;

EID: 84898486466     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-RV-112     Document Type: Review

References (66)

1. Ette, E. I. and Williams, P. J.: Pharmacometrics. In Ette, E. I. and Williams, P. J. (eds.), The Science of Quantitative Pharmacology, John Wiley & Sons, Inc., 2007.
2. Lee, J. Y., Garnett, C. E., Gobburu, J. V., Bhattaram, V. A., Brar, S., Earp, J. C., Jadhav, P. R., Krudys, K., Lesko, L. J., et al.: Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin. Pharmacokinet., 50: 627-635 (2011).
3. Gobburu, J. V. and Lesko, L. J.: Quantitative disease, drug, and trial models. Annu. Rev. Pharmacol. Toxicol., 49: 291-301 (2009).
4. Contemporary Issues in Clinical Pharmacology, The FDA Office of Clinical Pharmacology Experience, 2013.
5. Lesko, L. J. and Schmidt, S.: Individualization of drug therapy: history, present state, and opportunities for the future. Clin. Pharmacol. Ther., 92: 458-466 (2012).
6. Sherwin, C. M., Fukuda, T., Brunner, H. I., Goebel, J. and Vinks, A. A.: The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin. Pharmacokinet., 50: 1-24 (2011).
7. Staatz, C. E. and Tett, S. E.: Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet? Clin. Pharmacokinet., 50: 759-772 (2011).
8. Abd Rahman, A. N., Tett, S. E. and Staatz, C. E.: Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. Clin. Pharmacokinet., 52: 303-331 (2013).
9. Staatz, C. E. and Tett, S. E.: Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin. Pharmacokinet., 46: 13-58 (2007).
10. Tedesco-Silva, H., Bastien, M. C., Choi, L., Felipe, C., Campestrini, J., Picard, F. and Schmouder, R.: Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant. Proc., 37: 852-855 (2005).
11. Budde, K., Tedesco-Silva, H., Pestana, J. M., Glander, P., Neumayer, H. H., Felipe, C. R., Machado, P. P., Sechaud, R. and Schmouder, R.: Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring. Ther. Drug Monit., 29: 381-384 (2007).
12. Kuypers, D. R., Le Meur, Y., Cantarovich, M., Tredger, M. J., Tett, S. E., Cattaneo, D., Tonshoff, B., Holt, D. W., Chapman, J., et al.: Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin. J. Am. Soc. Nephrol., 5: 341-358 (2010).
13. Fleming, D. H., Mathew, B. S., Prasanna, S., Annapandian, V. M. and John, G. T.: A possible simplification for the estimation of area under the curve (AUC(0)(-)(1)(2)) of enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus. Ther. Drug Monit., 33: 165-170 (2011).
14. Shaw, L. M., Kaplan, B., DeNofrio, D., Korecka, M. and Brayman, K. L.: Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther. Drug Monit., 22: 14-19 (2000).
15. Shaw, L. M., Korecka, M., Venkataramanan, R., Goldberg, L., Bloom, R. and Brayman, K. L.: Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am. J. Transplant., 3: 534-542 (2003).
16. de Winter, B. C., Mathot, R. A., Sombogaard, F., Vulto, A. G. and van Gelder, T.: Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clin. J. Am. Soc. Nephrol., 6: 656-663 (2011).
17. Fukuda, T., Dong, M., de Vries, M. T., Cox, S., Goebel, J. and Vinks, A. A.: Population pharmacokinetic-pharmacodynamic model of mycophenolic acid with inosine monophosphate dehydrogenase activity following administration of mycophenolate mofetil in pediatric renal transplant recipients. Clin. Pharmacol. Ther., 91: S96-S135 (2012).
18. Tonshoff, B., David-Neto, E., Ettenger, R., Filler, G., van Gelder, T., Goebel, J., Kuypers, D. R., Tsai, E., Vinks, A. A., et al.: Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplant. Rev. (Orlando), 25: 78-89 (2011).
19. Fukuda, T., Brunner, H. I., Sagcal-Gironella, A. C. and Vinks, A. A.: Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Ther. Drug Monit., 33: 658-662 (2011).
20. Yang, W. S., Lee, J. M., Han, N. J., Kim, Y. J., Chang, J. W. and Park, S. K.: Mycophenolic acid attenuates tumor necrosis factor-alpha-induced endothelin-1 production in human aortic endothelial cells. Atherosclerosis, 211: 48-54 (2010).
21. Koehl, G. E., Wagner, F., Stoeltzing, O., Lang, S. A., Steinbauer, M., Schlitt, H. J. and Geissler, E. K.: Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability. Transplantation, 83: 607-614 (2007).
22. Kim, H., Long-Boyle, J., Rydholm, N., Orchard, P. J., Tolar, J., Smith, A. R., Jacobson, P. and Brundage, R.: Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation. J. Clin. Pharmacol., 52: 1665-1675 (2012).
23. Zhao, W., Fakhoury, M., Deschenes, G., Roussey, G., Brochard, K., Niaudet, P., Tsimaratos, M., Andre, J. L., Cloarec, S., et al.: Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J. Clin. Pharmacol., 50: 1280-1291 (2010).
24. Sherwin, C. M., Sagcal-Gironella, A. C., Fukuda, T., Brunner, H. I. and Vinks, A. A.: Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br. J. Clin. Pharmacol., 73: 727-740 (2012).
25. Li, H., Mager, D. E., Sandmaier, B. M., Maloney, D. G., Bemer, M. J. and McCune, J. S.: Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J. Clin. Pharmacol., 53: 393-402 (2013).
26. Li, H., Mager, D. E., Bemer, M. J., Salinger, D. H., Vicini, P., Sandmaier, B. M., Nash, R. and McCune, J. S.: A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients. J. Clin. Pharmacol., 52: 1654-1664 (2012).
27. Frymoyer, A., Verotta, D., Jacobson, P. and Long-Boyle, J.: Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. Br. J. Clin. Pharmacol., 75: 463-475 (2013).
28. Zhao, W., Elie, V., Baudouin, V., Bensman, A., Andre, J. L., Brochard, K., Broux, F., Cailliez, M., Loirat, C., et al.: Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. Br. J. Clin. Pharmacol., 69: 358-366 (2010).
29. Punyawudho, B., Lertdumrongluk, P., Somparn, P., Kittanamongkolchai, W., Traitanon, O., Avihingsanon, Y. and Vadcharavivad, S.: Population pharmacokinetics of mycophenolate mofetil in Thai lupus nephritis patients. Int. J. Clin. Pharmacol. Ther., 50: 272-280 (2012).
30. Sam, W. J. and Joy, M. S.: Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis. Ther. Drug Monit., 32: 594-605 (2010).
31. Jelliffe, R., Schumitzky, A. and Van Guilder, M.: Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods. Ther. Drug Monit., 22: 354-365 (2000).
32. Neely, M. N., van Guilder, M. G., Yamada, W. M., Schumitzky, A. and Jelliffe, R. W.: Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther. Drug Monit., 34: 467-476 (2012).
33. Jelliffe, R. W., Schumitzky, A., Van Guilder, M., Liu, M., Hu, L., Maire, P., Gomis, P., Barbaut, X. and Tahani, B.: Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther. Drug Monit., 15: 380-393 (1993).
34. Jelliffe, R. W., Schumitzky, A., Bayard, D., Milman, M., Van Guilder, M., Wang, X., Jiang, F., Barbaut, X. and Maire, P.: Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new ' multiple model' dosage design, bayesian feedback and individualised target goals. Clin. Pharmacokinet., 34: 57-77 (1998).
35. Premaud, A., Weber, L. T., Tonshoff, B., Armstrong, V. W., Oellerich, M., Urien, S., Marquet, P. and Rousseau, A.: Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. Pharmacol. Res., 63: 216-224 (2011).
36. Jelliffe, R., Neely, M., Schumitzky, A., Bayard, D., Van Guilder, M., Botnen, A., Bustad, A., Laing, D., Yamada, W., et al.: Nonparametric population modeling and Bayesian analysis. Pharmacol. Res., 64: 426 (2011).
37. Leong, R., Vieira, M. L., Zhao, P., Mulugeta, Y., Lee, C. S., Huang, S. M. and Burckart, G. J.: Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin. Pharmacol. Ther., 91: 926-931 (2012).
38. Rowland, M., Peck, C. and Tucker, G.: Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol., 51: 45-73 (2011).
39. Vinks, A. A.: The future of physiologically based pharmacokinetic modeling to predict drug exposure in pregnant women. CPT Pharmacometrics Syst. Pharmacol., 2: e33 (2013).
40. Jiao, Z., Ding, J. J., Shen, J., Liang, H. Q., Zhong, L. J., Wang, Y., Zhong, M. K. and Lu, W. Y.: Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. Br. J. Clin. Pharmacol., 65: 893-907 (2008).
41. Emoto, C., Fukuda, T., Cox, S., Christians, U. and Vinks, A. A.: Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content. CPT Pharmacometrics Syst. Pharmacol., 2: e59 (2013).
42. Ohtani, H., Barter, Z., Minematsu, T., Makuuchi, M., Sawada, Y. and Rostami-Hodjegan, A.: Bottom-up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. Biopharm. Drug Dispos., 32: 498-506 (2011).
43. Stemkens, R., Dong, M., Venkatasubramanian, R., Lukacova, V., Fraczkiewicz, G., Fukuda, T. and Vinks, A. A.: Physiologically based pharmacokinetic modeling of mycophenolic acid: improved prediction of absorption and enterohepatic recycling. Ther. Drug Monit., 35: 684-685 (2013).
44. Mathias, N. R. and Crison, J.: The use of modeling tools to drive efficient oral product design. AAPS J., 14 : 591-600 (2012).
45. Parrott, N. and Lave, T.: Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. Eur. J. Pharm. Sci., 17: 51-61 (2002).
46. Bullingham, R., Monroe, S., Nicholls, A. and Hale, M.: Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J. Clin. Pharmacol., 36: 315-324 (1996).
47. Neely, M. and Jelliffe, R.: Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J. Clin. Pharmacol., 50: 842-847 (2010).
48. Saint-Marcoux, F., Vandierdonck, S., Premaud, A., Debord, J., Rousseau, A. and Marquet, P.: Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients. Ther. Drug Monit., 33 : 285-294 (2011).
49. Daher Abdi, Z., Essig, M., Rizopoulos, D., Le Meur, Y., Premaud, A., Woillard, J. B., Rerolle, J. P., Marquet, P. and Rousseau, A.: Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant recipients using a joint modeling approach. Pharmacol. Res., 72: 52-60 (2013).
50. Mouksassi, M. S., Marier, J. F., Jonsson, F., Czerwiec, F., Levy, D., Chapman, A., Gitomer, B., Torres, V., Dennis, E., et al.: A Joint Modeling Framework for the Qualification of Total Kidney Volume as a Prognostic Biomarker for the Onset of End Stage Renal Disease in Patients with Autosomal Dominant Polycystic Kidney Disease, in American Conference of Pharmacometrics, 2013.
51. Wang, Y., Jadhav, P. R., Lala, M. and Gobburu, J. V.: Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J. Clin. Pharmacol., 52: 1601-1606 (2012).
52. Mentre, F., Chenel, M., Comets, E., Grevel, J., Hooker, A., Karlsson, M. O., Lavielle, M. and Gueorguieva, I.: Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members. CPT Pharmacometrics Syst. Pharmacol., 2: e46 (2013).
53. Barau, C., Furlan, V., Debray, D., Taburet, A. M. and Barrail-Tran, A.: Population Pharmacokinetics of Mycophenolic Acid and Dose Optimisation with Limited Sampling Strategy in Liver Transplant Children. Br. J. Clin. Pharmacol., 74: 515-524 (2012).
54. Sommerer, C., Muller-Krebs, S., Schaier, M., Glander, P., Budde, K., Schwenger, V., Mikus, G. and Zeier, M.: Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br. J. Clin. Pharmacol., 69: 346-357 (2010).
55. Musuamba, F. T., Mourad, M., Haufroid, V., De Meyer, M., Capron, A., Delattre, I. K., Verbeeck, R. K. and Wallemacq, P.: Statistical tools for dose individualization of mycophenolic acid and tacrolimus coadministered during the first month after renal transplantation. Br. J. Clin. Pharmacol., 75: 1277-1288 (2013).
56. Aarons, L. and Ogungbenro, K.: Optimal design of pharmacokinetic studies. Basic Clin. Pharmacol. Toxicol., 106 : 250-255 (2010).
57. Roy, A. and Ette, E. I.: A pragmatic approach to the design of population pharmacokinetic studies. AAPS J., 7: E408-E420 (2005).
58. D'Argenio, D. Z.: Optimal sampling times for pharmacokinetic experiments. J. Pharmacokinet. Biopharm., 9: 739-756 (1981).
59. Fukuda, T., Goebel, J., Thogersen, H., Maseck, D., Cox, S., Logan, B., Sherbotie, J., Seikaly, M. and Vinks, A. A.: Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J. Clin. Pharmacol., 51: 309-320 (2011).
60. Glander, P., Hambach, P., Braun, K. P., Fritsche, L., Giessing, M., Mai, I., Einecke, G., Waiser, J., Neumayer, H. H., et al.: Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am. J. Transplant., 4: 2045-2051 (2004).
61. Vethe, N. T., Bremer, S., Rootwelt, H. and Bergan, S.: Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. Ther. Drug Monit., 30: 647-655 (2008).
62. Budde, K., Glander, P., Hambach, P., Fritsche, L., Waiser, J., Braun, K. P. and Neumayer, H. H.: Predictive value of pretransplant IMPDH activity for MMF dosing. Am. J. Transplant., 4 s8: 254 (2004).
63. Bremer, S., Mandla, R., Vethe, N. T., Rasmussen, I., Rootwelt, H., Line, P. D., Midtvedt, K. and Bergan, S.: Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation, 85: 55-61 (2008).
64. Zeng, L., Blair, E. Y., Nath, C. E., Shaw, P. J., Earl, J. W., Stephen, K., Montgomery, K., Coakley, J. C., Hodson, E., et al.: Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. Br. J. Clin. Pharmacol., 70: 567-579 (2010).
65. Lamba, M., Tafti, B., Melcher, M., Chan, G., Krishnaswami, S. and Busque, S.: Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. Ther. Drug Monit., 32: 778-781 (2010).
66. Guillet, B. A., Simon, N. S., Purgus, R., Botta, C., Morange, S., Berland, Y. and Pisano, P. S.: Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction. Ther. Drug Monit., 32: 427-432 (2010).